Ear14 Inhibitors
Ear14, a gene predicted to enable ribonuclease activity and involved in chemotaxis and the innate immune response in mucosa, showcases its functional relevance in the extracellular space. Its orthology to human RNASE2 further emphasizes its conserved functionality. The multifaceted nature of Ear14's predicted functions hints at its potential role in diverse physiological processes, ranging from enzymatic activities to immune responses.
Understanding the general mechanisms of Ear14 inhibition unravels a tapestry of intricate cellular pathways targeted by specific chemical entities. These inhibitors act through diverse signaling cascades, modulating the expression and activity of Ear14 indirectly. The inhibition is achieved by disrupting key pathways such as the EGFR, NF-κB, actin-myosin contractility, thymidylate synthesis, PI3K/AKT, MAPK, mTOR, histone deacetylation, and JNK pathways. These pathways represent interconnected cellular networks, and the inhibitors exert their effects by influencing downstream effectors, altering gene expression patterns, and perturbing the delicate balance of cellular signaling. This nuanced approach to inhibition reflects the complexity of cellular regulation and provides a glimpse into the potential regulatory mechanisms governing Ear14 function. Importantly, these inhibitors, through their specific actions on various pathways, offer valuable tools for scientific investigations aiming to dissect the intricate roles of Ear14 in cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib, an EGFR inhibitor, disrupts the EGFR pathway, indirectly inhibiting Ear14 by altering downstream signaling and influencing gene expression within relevant cellular contexts. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082, an IKK inhibitor, interferes with the NF-κB pathway, influencing Ear14 expression by blocking the activation of transcription factors and subsequently impeding inflammatory responses. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Blebbistatin, a myosin II inhibitor, disrupts the actin-myosin contractility, indirectly impacting Ear14 by altering cellular morphology and influencing gene expression within relevant cellular contexts. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Fluorouracil, a thymidylate synthase inhibitor, disrupts DNA synthesis, indirectly inhibiting Ear14 by inducing DNA damage and altering cellular processes related to gene expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, disrupts the PI3K/AKT pathway, indirectly influencing Ear14 by modulating downstream effectors and interfering with the regulation of gene expression in relevant cellular contexts. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, modulates the MAPK pathway, impacting Ear14 indirectly by altering signaling cascades and gene expression within relevant cellular contexts. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, influences the mTOR pathway, indirectly inhibiting Ear14 by altering protein synthesis and cell cycle progression, leading to changes in gene expression within the cellular context. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, epigenetically regulates gene expression, indirectly inhibiting Ear14 by modulating chromatin structure and transcriptional control within the cellular environment. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, disrupts the PI3K/AKT pathway, indirectly influencing Ear14 by modulating downstream effectors and interfering with the regulation of gene expression in relevant cellular contexts. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin, a DNA cross-linking agent, disrupts DNA synthesis, indirectly inhibiting Ear14 by inducing DNA damage and altering cellular processes related to gene expression. | ||||||